|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DLL1 |
Gene summary for DLL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DLL1 | Gene ID | 28514 |
| Gene name | delta like canonical Notch ligand 1 | |
| Gene Alias | DELTA1 | |
| Cytomap | 6q27 | |
| Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | O00548 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 28514 | DLL1 | C04 | Human | Oral cavity | OSCC | 6.60e-16 | 1.01e+00 | 0.2633 |
| 28514 | DLL1 | C21 | Human | Oral cavity | OSCC | 4.92e-05 | 2.98e-01 | 0.2678 |
| 28514 | DLL1 | C30 | Human | Oral cavity | OSCC | 2.34e-16 | 8.14e-01 | 0.3055 |
| 28514 | DLL1 | C43 | Human | Oral cavity | OSCC | 1.55e-05 | 2.31e-01 | 0.1704 |
| 28514 | DLL1 | C51 | Human | Oral cavity | OSCC | 1.89e-08 | 5.93e-01 | 0.2674 |
| 28514 | DLL1 | C06 | Human | Oral cavity | OSCC | 8.45e-07 | 1.59e+00 | 0.2699 |
| 28514 | DLL1 | C09 | Human | Oral cavity | OSCC | 7.24e-05 | 3.63e-01 | 0.1431 |
| 28514 | DLL1 | LP17 | Human | Oral cavity | LP | 2.23e-02 | 4.37e-01 | 0.2349 |
| 28514 | DLL1 | SYSMH2 | Human | Oral cavity | OSCC | 4.25e-04 | 3.61e-01 | 0.2326 |
| 28514 | DLL1 | SYSMH3 | Human | Oral cavity | OSCC | 2.05e-22 | 5.93e-01 | 0.2442 |
| 28514 | DLL1 | P1_cSCC | Human | Skin | cSCC | 3.49e-12 | 6.68e-01 | 0.0292 |
| 28514 | DLL1 | P2_cSCC | Human | Skin | cSCC | 3.56e-04 | 2.43e-01 | -0.024 |
| 28514 | DLL1 | P4_cSCC | Human | Skin | cSCC | 3.41e-02 | 2.03e-01 | -0.00290000000000005 |
| 28514 | DLL1 | P10_cSCC | Human | Skin | cSCC | 6.09e-10 | 5.06e-01 | 0.1017 |
| 28514 | DLL1 | cSCC_p11 | Human | Skin | cSCC | 6.18e-03 | 1.84e-01 | -0.2102 |
| 28514 | DLL1 | cSCC_p7 | Human | Skin | cSCC | 4.55e-02 | 1.46e-01 | -0.2332 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003009920 | Oral cavity | OSCC | myeloid cell differentiation | 213/7305 | 381/18723 | 1.24e-11 | 4.42e-10 | 213 |
| GO:003010016 | Oral cavity | OSCC | regulation of endocytosis | 121/7305 | 211/18723 | 4.74e-08 | 8.80e-07 | 121 |
| GO:00435887 | Oral cavity | OSCC | skin development | 143/7305 | 263/18723 | 2.77e-07 | 4.27e-06 | 143 |
| GO:00085449 | Oral cavity | OSCC | epidermis development | 171/7305 | 324/18723 | 2.89e-07 | 4.43e-06 | 171 |
| GO:00987277 | Oral cavity | OSCC | maintenance of cell number | 81/7305 | 134/18723 | 3.96e-07 | 5.90e-06 | 81 |
| GO:00198276 | Oral cavity | OSCC | stem cell population maintenance | 79/7305 | 131/18723 | 6.28e-07 | 8.96e-06 | 79 |
| GO:0034349 | Oral cavity | OSCC | glial cell apoptotic process | 16/7305 | 17/18723 | 3.07e-06 | 3.72e-05 | 16 |
| GO:19031316 | Oral cavity | OSCC | mononuclear cell differentiation | 210/7305 | 426/18723 | 8.44e-06 | 9.02e-05 | 210 |
| GO:00099139 | Oral cavity | OSCC | epidermal cell differentiation | 109/7305 | 202/18723 | 1.08e-05 | 1.14e-04 | 109 |
| GO:00420635 | Oral cavity | OSCC | gliogenesis | 154/7305 | 301/18723 | 1.10e-05 | 1.14e-04 | 154 |
| GO:000206419 | Oral cavity | OSCC | epithelial cell development | 116/7305 | 220/18723 | 2.34e-05 | 2.21e-04 | 116 |
| GO:0034350 | Oral cavity | OSCC | regulation of glial cell apoptotic process | 11/7305 | 11/18723 | 3.17e-05 | 2.87e-04 | 11 |
| GO:004580710 | Oral cavity | OSCC | positive regulation of endocytosis | 59/7305 | 100/18723 | 3.99e-05 | 3.48e-04 | 59 |
| GO:00507679 | Oral cavity | OSCC | regulation of neurogenesis | 179/7305 | 364/18723 | 4.49e-05 | 3.84e-04 | 179 |
| GO:190370618 | Oral cavity | OSCC | regulation of hemopoiesis | 180/7305 | 367/18723 | 5.16e-05 | 4.30e-04 | 180 |
| GO:000689810 | Oral cavity | OSCC | receptor-mediated endocytosis | 125/7305 | 244/18723 | 6.56e-05 | 5.32e-04 | 125 |
| GO:00456825 | Oral cavity | OSCC | regulation of epidermis development | 41/7305 | 65/18723 | 7.29e-05 | 5.73e-04 | 41 |
| GO:00072196 | Oral cavity | OSCC | Notch signaling pathway | 92/7305 | 172/18723 | 7.84e-05 | 6.08e-04 | 92 |
| GO:00300983 | Oral cavity | OSCC | lymphocyte differentiation | 179/7305 | 374/18723 | 2.74e-04 | 1.74e-03 | 179 |
| GO:00456045 | Oral cavity | OSCC | regulation of epidermal cell differentiation | 36/7305 | 58/18723 | 3.15e-04 | 1.96e-03 | 36 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa043305 | Oral cavity | OSCC | Notch signaling pathway | 44/3704 | 62/8465 | 1.26e-05 | 5.55e-05 | 2.83e-05 | 44 |
| hsa015226 | Oral cavity | OSCC | Endocrine resistance | 63/3704 | 98/8465 | 3.09e-05 | 1.31e-04 | 6.67e-05 | 63 |
| hsa0433012 | Oral cavity | OSCC | Notch signaling pathway | 44/3704 | 62/8465 | 1.26e-05 | 5.55e-05 | 2.83e-05 | 44 |
| hsa0152214 | Oral cavity | OSCC | Endocrine resistance | 63/3704 | 98/8465 | 3.09e-05 | 1.31e-04 | 6.67e-05 | 63 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| DLL1 | NOTCH2 | DLL1_NOTCH2 | NOTCH | Breast | ADJ |
| DLL1 | NOTCH1 | DLL1_NOTCH1 | NOTCH | CRC | CRC |
| DLL1 | NOTCH3 | DLL1_NOTCH3 | NOTCH | CRC | CRC |
| DLL1 | NOTCH2 | DLL1_NOTCH2 | NOTCH | CRC | CRC |
| DLL1 | NOTCH1 | DLL1_NOTCH1 | NOTCH | CRC | MSS |
| DLL1 | NOTCH3 | DLL1_NOTCH3 | NOTCH | CRC | MSS |
| DLL1 | NOTCH4 | DLL1_NOTCH4 | NOTCH | CRC | MSS |
| DLL1 | NOTCH1 | DLL1_NOTCH1 | NOTCH | HNSCC | ADJ |
| DLL1 | NOTCH3 | DLL1_NOTCH3 | NOTCH | HNSCC | ADJ |
| DLL1 | NOTCH4 | DLL1_NOTCH4 | NOTCH | HNSCC | ADJ |
| DLL1 | NOTCH2 | DLL1_NOTCH2 | NOTCH | HNSCC | ADJ |
| DLL1 | NOTCH1 | DLL1_NOTCH1 | NOTCH | HNSCC | OSCC |
| DLL1 | NOTCH4 | DLL1_NOTCH4 | NOTCH | HNSCC | OSCC |
| DLL1 | NOTCH2 | DLL1_NOTCH2 | NOTCH | HNSCC | OSCC |
| DLL1 | NOTCH1 | DLL1_NOTCH1 | NOTCH | HNSCC | Precancer |
| DLL1 | NOTCH3 | DLL1_NOTCH3 | NOTCH | HNSCC | Precancer |
| DLL1 | NOTCH4 | DLL1_NOTCH4 | NOTCH | HNSCC | Precancer |
| DLL1 | NOTCH2 | DLL1_NOTCH2 | NOTCH | HNSCC | Precancer |
| DLL1 | NOTCH3 | DLL1_NOTCH3 | NOTCH | Lung | AAH |
| DLL1 | NOTCH4 | DLL1_NOTCH4 | NOTCH | Lung | AAH |
| Page: 1 2 3 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DLL1 | SNV | Missense_Mutation | rs372640222 | c.1156N>A | p.Asp386Asn | p.D386N | O00548 | protein_coding | tolerated(0.78) | benign(0.16) | TCGA-A2-A0T1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | herceptin | SD |
| DLL1 | SNV | Missense_Mutation | rs200861263 | c.1747N>C | p.Cys583Arg | p.C583R | O00548 | protein_coding | tolerated(0.45) | benign(0.017) | TCGA-A2-A0T5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
| DLL1 | SNV | Missense_Mutation | novel | c.1484N>G | p.Thr495Ser | p.T495S | O00548 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-A2-A3XZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| DLL1 | SNV | Missense_Mutation | novel | c.1036C>A | p.Leu346Ile | p.L346I | O00548 | protein_coding | tolerated(0.12) | benign(0.173) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DLL1 | SNV | Missense_Mutation | novel | c.494N>A | p.Ser165Asn | p.S165N | O00548 | protein_coding | tolerated(0.08) | benign(0.428) | TCGA-B6-A400-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| DLL1 | SNV | Missense_Mutation | c.140N>A | p.Gly47Glu | p.G47E | O00548 | protein_coding | tolerated(0.39) | benign(0.037) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| DLL1 | SNV | Missense_Mutation | rs370005717 | c.1793N>A | p.Arg598His | p.R598H | O00548 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| DLL1 | SNV | Missense_Mutation | c.1792N>A | p.Arg598Ser | p.R598S | O00548 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-E2-A15D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| DLL1 | insertion | In_Frame_Ins | novel | c.2151_2152insACAAACACTGCCTTTATTGTCCTTTTTGATACGAAGATG | p.Cys717_Val718insThrAsnThrAlaPheIleValLeuPheAspThrLysMet | p.C717_V718insTNTAFIVLFDTKM | O00548 | protein_coding | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | ||
| DLL1 | insertion | Frame_Shift_Ins | novel | c.2096_2097insCCAGGATGGAAAGAGGGCGACCG | p.Lys700GlnfsTer28 | p.K700Qfs*28 | O00548 | protein_coding | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |